These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35721187)

  • 1. Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
    Mainz JG; Zagoya C; Polte L; Naehrlich L; Sasse L; Eickmeier O; Smaczny C; Barucha A; Bechinger L; Duckstein F; Kurzidim L; Eschenhagen P; Caley L; Peckham D; Schwarz C
    Front Pharmacol; 2022; 13():877118. PubMed ID: 35721187
    [No Abstract]   [Full Text] [Related]  

  • 2. Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire.
    Mainz JG; Barucha A; Huang P; Bechinger L; Duckstein F; Polte L; Sadrieh P; Nährlich L; Eickmeier O; Van Dullemen S; Eschenhagen P; Schwarz C; Lüth S; Zagoya C; Graepler-Mainka U
    Front Pharmacol; 2023; 14():1167407. PubMed ID: 38026920
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study.
    Mainz JG; Lester K; Elnazir B; Williamson M; McKone E; Cox D; Linnane B; Zagoya C; Duckstein F; Barucha A; Davies JC; McNally P;
    J Cyst Fibros; 2024 May; 23(3):474-480. PubMed ID: 37806792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abdominal Symptoms Assessed With the CFAbd-Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis.
    Jaudszus A; Pfeifer E; Lorenz M; Beiersdorf N; Hipler UC; Zagoya C; Mainz JG
    J Pediatr Gastroenterol Nutr; 2022 Mar; 74(3):355-360. PubMed ID: 34789668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
    Mainz JG; Zagoya C; Polte L; Naehrlich L; Sasse L; Eickmeier O; Smaczny C; Barucha A; Bechinger L; Duckstein F; Kurzidim L; Eschenhagen P; Caley L; Peckham D; Schwarz C
    Front Pharmacol; 2023; 14():1207356. PubMed ID: 37205908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis.
    Caley LR; Zagoya C; Duckstein F; White H; Shimmin D; Jones AM; Barrett J; Whitehouse JL; Floto RA; Mainz JG; Peckham DG
    J Cyst Fibros; 2023 Mar; 22(2):275-281. PubMed ID: 36710099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature.
    Tupayachi Ortiz MG; Baumlin N; Yoshida M; Salathe M
    Heliyon; 2024 Mar; 10(5):e26955. PubMed ID: 38463894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis.
    Piehler L; Thalemann R; Lehmann C; Thee S; Röhmel J; Syunyaeva Z; Stahl M; Mall MA; Graeber SY
    Front Pharmacol; 2023; 14():1179208. PubMed ID: 37153809
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry.
    Sutharsan S; Dillenhoefer S; Welsner M; Stehling F; Brinkmann F; Burkhart M; Ellemunter H; Dittrich AM; Smaczny C; Eickmeier O; Kappler M; Schwarz C; Sieber S; Naehrig S; Naehrlich L;
    Lancet Reg Health Eur; 2023 Sep; 32():100690. PubMed ID: 37554663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor.
    Gruber W; Stehling F; Blosch C; Dillenhoefer S; Olivier M; Brinkmann F; Koerner-Rettberg C; Sutharsan S; Mellies U; Taube C; Welsner M
    Front Sports Act Living; 2024; 6():1284878. PubMed ID: 38463712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A grumbling concern: an international survey of gastrointestinal symptoms in cystic fibrosis in the modulator era.
    Calthorpe RJ; Goodchild N; Gleetus V; Premakumar V; Hayee B; Elliott Z; Evans B; Rowbotham NJ; Carr SB; Barr H; Horsley A; Peckham D; Smyth AR
    NIHR Open Res; 2023; 3():18. PubMed ID: 37881465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S
    Front Immunol; 2023; 14():1107437. PubMed ID: 36875141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy.
    Hilliam Y; Armbruster CR; Rapsinski GJ; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Cooper VS; Lee SE; Bomberger JM
    Microbiol Spectr; 2024 Jun; ():e0078724. PubMed ID: 38916354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score).
    Jaudszus A; Zeman E; Jans T; Pfeifer E; Tabori H; Arnold C; Michl RK; Lorenz M; Beiersdorf N; Mainz JG
    Patient; 2019 Aug; 12(4):419-428. PubMed ID: 30887269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome.
    Marsh R; Dos Santos C; Hanson L; Ng C; Major G; Smyth AR; Rivett D; van der Gast C
    Microbiol Spectr; 2023 Aug; 11(5):e0117523. PubMed ID: 37607068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study.
    Fila L; Grandcourtova A; Bilkova A; Drevinek P
    Front Pharmacol; 2023; 14():1178009. PubMed ID: 37332357
    [No Abstract]   [Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor.
    Tsai A; Wu SP; Haseltine E; Kumar S; Moskowitz SM; Panorchan P; Shah K
    Pulm Ther; 2020 Dec; 6(2):275-286. PubMed ID: 32734574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.